Table 1 Disposition of patients
Study medication disposition, n (%) | Omarigliptin 25 mg N = 2100 | Placebo N = 2102 |
|---|---|---|
Did not take study medication | 8 (0.4) | 2 (0.1) |
Discontinued study medication | 2092 (99.6) | 2100 (99.9) |
Adverse event | 88 (4.2) | 74 (3.5) |
Death | 48 (2.3) | 37 (1.8) |
Lack of efficacy | 9 (0.4) | 14 (0.7) |
Lost to follow-up | 44 (2.1) | 54 (2.6) |
Non-compliance with study drug | 10 (0.5) | 6 (0.3) |
Physician decision | 25 (1.2) | 33 (1.6) |
Progressive disease | 2 (0.1) | 1 (0.0) |
Protocol violation | 7 (0.3) | 14 (0.7) |
Study terminated by sponsor | 1615 (76.9) | 1602 (76.2) |
Withdrawal by patient | 197 (9.4) | 213 (10.1) |
Other | 47 (2.2) | 52 (2.5) |